A low-dose arsenic-induced p53 protein-mediated metabolic mechanism of radiotherapy protection

J Biol Chem. 2014 Feb 21;289(8):5340-7. doi: 10.1074/jbc.M113.531020. Epub 2014 Jan 3.

Abstract

Radiotherapy is the current frontline cancer treatment, but the resulting severe side effects often pose a significant threat to cancer patients, raising a pressing need for the development of effective strategies for radiotherapy protection. We exploited the distinct metabolic characteristics between normal and malignant cells for a metabolic mechanism of normal tissue protection. We showed that low doses of arsenic induce HIF-1α, which activates a metabolic shift from oxidative phosphorylation to glycolysis, resulting in increased cellular resistance to radiation. Of importance is that low-dose arsenic-induced HIF-1α requires functional p53, limiting the glycolytic shift to normal cells. Using tumor-bearing mice, we provide proof of principle for selective normal tissue protection against radiation injury.

Keywords: DNA Damage; Glycolysis; Metabolism; Signal Transduction; p53.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Arsenic / pharmacology*
  • Cell Line, Tumor
  • Dose-Response Relationship, Drug
  • Glycolysis / drug effects
  • Glycolysis / radiation effects
  • Humans
  • Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
  • Metabolism / drug effects*
  • Metabolism / radiation effects
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • NF-kappa B / metabolism
  • Radiation Tolerance / drug effects
  • Radiation Tolerance / radiation effects
  • Radiation-Protective Agents / pharmacology*
  • Tumor Suppressor Protein p53 / metabolism*
  • Whole-Body Irradiation

Substances

  • Hypoxia-Inducible Factor 1, alpha Subunit
  • NF-kappa B
  • Radiation-Protective Agents
  • Tumor Suppressor Protein p53
  • Arsenic